BRPI1008083B8 - processo para a produção de uma linhagem de células amniócitos humanas permanentes, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego da referida linhagem de células, e emprego da referida linhagem de células - Google Patents

processo para a produção de uma linhagem de células amniócitos humanas permanentes, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego da referida linhagem de células, e emprego da referida linhagem de células

Info

Publication number
BRPI1008083B8
BRPI1008083B8 BRPI1008083A BRPI1008083A BRPI1008083B8 BR PI1008083 B8 BRPI1008083 B8 BR PI1008083B8 BR PI1008083 A BRPI1008083 A BR PI1008083A BR PI1008083 A BRPI1008083 A BR PI1008083A BR PI1008083 B8 BRPI1008083 B8 BR PI1008083B8
Authority
BR
Brazil
Prior art keywords
cell line
proteins
transient expression
recombinant polypeptides
production
Prior art date
Application number
BRPI1008083A
Other languages
English (en)
Inventor
Volpers Christoph
Schiedner Gudrun
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of BRPI1008083A2 publication Critical patent/BRPI1008083A2/pt
Publication of BRPI1008083B1 publication Critical patent/BRPI1008083B1/pt
Publication of BRPI1008083B8 publication Critical patent/BRPI1008083B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

processo para a produção de uma linhagem de células amniócitos humanas permanentes, linhagem de células humanas aminióciticas, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego de uma linhagem, emprego das células e polipeptídeo ou proteína. a presente invenção se refere a uma linhagem de células humanas permanente, compreendendo as sequências de ácidos nucleicos para as funções genéticas adenovirais e1a e e1b e a sequência de ácidos nucleicos para o antígeno t grande de sv40 ou o antígeno-1 nuclear do vírus de epstein-barr (ebv) (ebna-1). a presente invenção se refere ainda a um processo para a expressão transitória de polipeptídeos e proteínas recombinantes na linhagem de células humanas permanentes.
BRPI1008083A 2009-02-05 2010-02-05 processo para a produção de uma linhagem de células amniócitos humanas permanentes, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego da referida linhagem de células, e emprego da referida linhagem de células BRPI1008083B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009003439A DE102009003439A1 (de) 2009-02-05 2009-02-05 Neue permanente humane Zelllinie
DE102009003439.0 2009-02-05
PCT/DE2010/075012 WO2010094280A1 (de) 2009-02-05 2010-02-05 Neue permanente humane zelllinie

Publications (3)

Publication Number Publication Date
BRPI1008083A2 BRPI1008083A2 (pt) 2016-10-11
BRPI1008083B1 BRPI1008083B1 (pt) 2020-08-18
BRPI1008083B8 true BRPI1008083B8 (pt) 2021-05-25

Family

ID=42316055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008083A BRPI1008083B8 (pt) 2009-02-05 2010-02-05 processo para a produção de uma linhagem de células amniócitos humanas permanentes, processo para a expressão transitória de polipeptídeos e proteínas recombinantes com o emprego da referida linhagem de células, e emprego da referida linhagem de células

Country Status (20)

Country Link
US (1) US9371512B2 (pt)
EP (2) EP2393919B1 (pt)
JP (1) JP2012516690A (pt)
KR (1) KR101695349B1 (pt)
CN (1) CN102369279A (pt)
AU (1) AU2010214951B2 (pt)
BR (1) BRPI1008083B8 (pt)
CA (1) CA2751497C (pt)
DE (2) DE102009003439A1 (pt)
DK (2) DK2913395T3 (pt)
ES (2) ES2642837T3 (pt)
HU (1) HUE036707T2 (pt)
IL (1) IL214421A (pt)
LT (1) LT2913395T (pt)
PL (2) PL2393919T3 (pt)
PT (2) PT2913395T (pt)
RU (1) RU2569181C2 (pt)
SG (1) SG173484A1 (pt)
TW (1) TW201033363A (pt)
WO (1) WO2010094280A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404090B2 (en) * 2011-11-24 2016-08-02 Viromed Co., Ltd. Adenovirus producing novel cell line and the use thereof
WO2014115087A2 (en) * 2013-01-22 2014-07-31 Cencor Biotech Ltd. A method for the preparation of recombinant human prothrombin and fibrinogen
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
AU2020342349A1 (en) 2019-09-02 2022-03-03 Biotest Ag Factor VIII protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658763A (en) * 1993-10-25 1997-08-19 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) * 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
RU2267538C2 (ru) * 2000-09-08 2006-01-10 Айова Стейт Юниверсити Рисерч Фаундейшн, Инк. Способ скрининга животных с повышенным уровнем численности приплода и/или предпочтительными признаками качества мяса, белок prkag3 (варианты) и кодирующая его нуклеотидная последовательность (варианты)
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien

Also Published As

Publication number Publication date
DE102009003439A1 (de) 2010-08-26
EP2913395A1 (de) 2015-09-02
EP2913395B1 (de) 2017-08-16
PT2393919E (pt) 2015-10-12
WO2010094280A1 (de) 2010-08-26
CA2751497C (en) 2017-03-28
EP2393919B1 (de) 2015-07-08
PT2913395T (pt) 2017-10-19
PL2913395T3 (pl) 2018-01-31
CA2751497A1 (en) 2010-08-26
BRPI1008083A2 (pt) 2016-10-11
ES2642837T3 (es) 2017-11-20
BRPI1008083B1 (pt) 2020-08-18
LT2913395T (lt) 2017-09-11
JP2012516690A (ja) 2012-07-26
IL214421A (en) 2016-09-29
DK2913395T3 (en) 2017-10-16
KR20110116198A (ko) 2011-10-25
PL2393919T3 (pl) 2015-12-31
US9371512B2 (en) 2016-06-21
RU2569181C2 (ru) 2015-11-20
EP2393919A1 (de) 2011-12-14
AU2010214951A1 (en) 2011-08-18
US20120040400A1 (en) 2012-02-16
HUE036707T2 (hu) 2018-07-30
SG173484A1 (en) 2011-09-29
IL214421A0 (en) 2011-09-27
RU2011136451A (ru) 2013-03-10
DK2393919T3 (en) 2015-09-21
KR101695349B1 (ko) 2017-01-11
CN102369279A (zh) 2012-03-07
PL2913395T4 (pl) 2018-03-30
ES2547700T3 (es) 2015-10-08
TW201033363A (en) 2010-09-16
AU2010214951B2 (en) 2016-01-28
DE112010000285A5 (de) 2012-09-20

Similar Documents

Publication Publication Date Title
Gjoerup et al. Update on human polyomaviruses and cancer
IL222452B (en) A process for preparing a recombinant polypeptide by growing mammalian cells in a serum-free and protein-free cell culture medium
MX376623B (es) Cultivo celular metabolicamente optimizado.
TR201900213T4 (tr) Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu.
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
WO2009091912A3 (en) Improved mammalian expression vectors and uses thereof
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
MX355650B (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
BR112014020694A2 (pt) proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
EP2142560A4 (en) RECOMBINANT EXPRESSION VECTOR ELEMENTS (REVE) FOR INCREASING THE EXPRESSION OF RECOMBINANT PROTEINS IN HOST CELLS
BR112012013875B8 (pt) método in vitro para reprogramar células somáticas humanas ou de outros mamíferos para células tronco pluripotentes induzidas (células ips ou ipscs) e composição
ATE412761T1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
WO2011115420A3 (en) Adhesive extracellular matrix mimetic
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112014015933A2 (pt) métodos e materiais para reduzir a degradação das proteínas recombinantes
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells
AU2010291066A8 (en) Protein glycosylation
EP2935581A4 (en) EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS
MY162335A (en) Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
IN2014MN02500A (pt)
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
EP4589002A3 (en) Use of monensin to regulate glycosylation of recombinant proteins

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF